RecruitingPhase 1NCT05787587
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
Sponsor
IDEAYA Biosciences
Enrollment
216 participants
Start Date
Apr 18, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This study is testing a new drug called IDE161 — a PARG inhibitor — in people with advanced solid tumors. PARG is an enzyme that helps cancer cells repair their DNA; blocking it may make cancer cells more vulnerable to dying. This trial focuses particularly on people with certain DNA repair gene mutations.
**You may be eligible if...**
- You are 18 or older with advanced or metastatic solid tumor cancer (not a primary brain tumor)
- Your cancer has progressed after at least one prior standard treatment
- For one study module: your tumor has mutations in BRCA1/2 or other DNA repair genes (like ATM, PALB2, CHEK2, etc.)
- For another module: you have advanced endometrial cancer that has progressed after immunotherapy
**You may NOT be eligible if...**
- Your cancer originated in the brain
- You have serious gastrointestinal problems affecting medication absorption
- You have active, uncontrolled infections
- You have significant heart problems
- You have had major surgery, radiation, or chemotherapy very recently
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGIDE-161
Oral Medication
DRUGPembrolizumab
Intravenous Infusion
Locations(27)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05787587
Related Trials
A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs
NCT0733644618 locations
Multiparametric Magnetic Resonance Imaging of the Prostate to Assess Disease Progression and Genomics in Patients Undergoing Active Surveillance for Prostate Cancer
NCT046926751 location
DESTINY-PANTUMOUR04
NCT0712400017 locations
A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer
NCT0700515433 locations
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT0621891418 locations